A New Class of Heterocycles: 1,4,3,5-Oxathiadiazepane 4,4-dioxides

Amel Bendjeddou 1,*, Tahar Abbaz 2, Zine Regainia 1 and Nour-Eddine Aouf 1

1 Laboratoire de Chimie Organique Appliquée, Groupe de chimie Hétérocyclique, Département de Chimie, Faculté des Sciences, Université d’Annaba, BP 12, 23000, Algérie
2 Laboratoire de Chimie des Matériaux Organiques, Université de Tébessa, Route de Constantine, Tébessa, 12000, Algérie

* Author to whom correspondence should be addressed; E-Mail: bendjeddouamel@gmail.com; Fax: +213-3095-2935.

Received: 19 January 2012; in revised form: 6 February 2012 / Accepted: 8 February 2012 / Published: 14 February 2012

Abstract: This work reports the synthesis of novel 1,4,3,5-oxathiadiazepanes 4,4-dioxides from the reaction of N’-benzyl-N-(2-hydroxyethyl)-sarcosine or proline sulfamide with aromatic aldehydes under acid catalysis. To prepare the starting materials N-Boc-sulfamide derivatives of sarcosine or proline were alkylated with benzyl alcohol under Mitsunobu reaction conditions, the Boc group was removed chemoselectively by acidolysis, and the resulting product reduced to the corresponding alcohol in good yields.

Keywords: cyclic sulfamides; benzodithiazine dioxides; benzoaxathiazepine dioxides

1. Introduction

Sulfamides and their analogs have a rich chemical and biological history and have emerged as a promising class of compounds in drug discovery [1,2]. Sultams (cyclic sulfamides), although not found in Nature, have also shown potent biological activity, including several displaying a wide spectrum of activities [3,4]. The more prominent include a number of benzodithiazine dioxides and benzoaxathiazepine 1,1-dioxides displaying anti-HIV-1 activity [5] and the ability to activate glucokinase [6] (type II diabetes), respectively.

In addition, pyrrolo[2,1-c]benzodiazepine antibiotics and some of their heterocyclic analogs show anticancer activity [7–10], it has been proposed that the cytotoxicity and antitumour activity of these...
compounds results from the formation of a covalent bond between the azomethine unit of the diazepine ring and the C(2)-amino group guanine nucleus in the minor groove of the DNA double spiral [11–14]. In a continuous of previous work [15–19], we have described a convenient access to a series of n-membered cyclic sulfamides A and heterocyclic constrained peptides containing sulfamide groups B, starting from natural amino acids, chloroethylamine and chlorosulfonylisocyanate (CSI). In continuation of our efforts to design and synthesize new cyclic sulfamides, we have extended our studies to a series of seven membered heterocyclic compounds C containing sulfamide groups (Figure 1), we describe for the first time the first example of a new heterocyclic class 1,4,3,5-oxathiadiazepane 4,4-dioxides which can be described as structural analogs of the anti-HIV-1 compounds mentioned above. This compound is an interesting candidate for pharmaceutical purposes.

![Figure 1. Cyclosulfamide structures.](image)

2. Results and Discussion

In recent years, considerable attention was paid to compounds resulting from the condensation of substituted amino alcohols with aldehydes [20–24]. As outlined in Scheme 1, the substituted amino alcohols (N'-benzyl-N-(2-hydroxyethyl)-proline or sarcosine sulfamides) 1c and 2c were prepared in a three-step reaction sequence starting from (tert-butyloxycarbonylsulfonyl) L-amino acid methyl esters 1 and 2. These compounds were synthesized by sulfamoylation of aminoester derivatives (Pro, Sar) as previously described [18].

![Scheme 1. General synthesis of substituted aminoalcohol sulfamides.](image)

Reagents and conditions: (i) PhCH2OH (1 equiv.), PPh3 (1.5 equiv.), DIAD or DEAD (1.5 equiv.), THF; (ii) TFA (3 equiv.), CH2Cl2; (iii) NaBH4 (2 equiv.), THF-Eau (4:1).
In these tert-butyloxy carbonylsulfamides 1 and 2, the Boc (tert-butyloxy carbonyl) group increases the acidity of the adjacent NH group and allows an expedient regiospecific alkylation under Mitsunobu conditions [25–28] using benzylic alcohol, which provides the N-substituted Boc-sulfamides 1a and 2a in 80% and 85% yield, respectively. Selective cleavage of the tert-butyloxy carbonyl protective group with trifluoroacetic acid gives compounds 1b and 2b in 95% and 98% yield, respectively. The substituted amino alcohols sulfamides 1c and 2c were obtained from the deprotected sulfamides by NaBH₄ reduction in 87% and 85% yield, respectively.

Substituted 1,4,3,5-oxathiadiazepane 4,4-dioxides were obtained in accordance with the methodology shown in the literature [20]. The substituted amino alcohols 1c and 2c were allowed to react with aromatic aldehydes in dichloromethane in a cyclodehydration reaction to obtain the corresponding compounds 1d–4d, 1e–4e. The yields are listed in Table 1. These compounds can furnish after debenzylation new ring opened products by nucleophilic attack by organometallic reagents [27,28].

Table 1. General synthesis of substituted oxathiadiazepane 4,4-dioxides.

| Compounds | Yield (%) |
|-----------|-----------|
| 1d        | 50        |
| 2d        | 50        |
| 3d        | 43        |
| 4d        | 41        |
| 1e        | 55        |
| 2e        | 45        |
| 3e        | 40        |
| 4e        | 42        |

Reagents and conditions: (iv) Aromatic aldehyde (1 equiv.), CH₂Cl₂, H₂SO₄ cat.

In the ¹H-NMR (CDCl₃) spectra of proline derivatives 1e–4e, the asymmetric carbon protons of compounds 3e and 4e resonate around δ 6.52–6.35 ppm as a singlet peak. Compounds 1e and 2e exhibit a doublet of doublets at δ ~ 5.48 ppm and 7.90 ppm, with coupling constants of 3.43, 3.49 Hz and 1.53, 1.57 Hz, respectively. Thus, the asymmetric carbon proton of sarcosine derivatives, showed for compounds 3d and 4d a doublet at δ ~ 7.90 ppm and δ ~ 7.50 ppm with coupling constants of 1.47 Hz and 1.49 Hz, respectively, while compound 2d exhibit a doublet of doublets at δ ~ 7.80 ppm with coupling constants of 1.37, 1.55 Hz, and compound 1d presents a triplet at δ ~ 5.10 ppm.
3. Experimental

3.1. General

All commercial chemicals and solvents were used as received. Melting points were determined in open tubes on a Büchi apparatus and are uncorrected. IR spectra were recorded on a Perkin-Elmer Spectrum 1000 spectrophotometer. Microanalyses were performed in the Microanalysis Laboratory of ENSCM (Montpellier). $^1$H and $^{13}$C-Nuclear Magnetic Resonance spectra were determined on a Bruker AC 250 spectrometer. Chemical shifts are recorded in ppm ($\delta$) and coupling constants ($J$) in Hertz, relative to tetramethylsilane used as internal standard. Multiplicity is indicated as s (singlet), d (doublet), q (quadruplet), m (multiplet) and combinations of these signals. Fast-atom bombardment mass spectra (FAB) were recorded in positive or negative mode with glycerol (G), thioglycerol (GT), or 3-nitrobenzylalcohol (NOBA) as matrix. Optical rotations for solutions in CHCl$_3$ were measured with a POLAX model 2L digital polarimeter. All reactions were monitored by Thin Layer Chromatography (TLC) on silica gel Merck 60 F$_{254}$ precoated aluminium plates, developed by spraying with ninhydrin solution. Column chromatography was performed using silica gel 60 (203–400 mesh).

3.2. General Synthetic Procedure for Carbamoylation-Sulfamoylation: Preparation of 1 and 2

A solution of $N$-chlorosulfonyl tert-butylcarbamate (0.05 mol) was prepared by addition of tert-butanol (408 mL in 50 mL of dichloromethane) to a solution of CSI (7.1 g in the same solvent). The resulting Boc-sulfamoyl chloride solution (25 mL) and triethylamine (17.40 g, 17.1 mL, 0.085 mol) in dichloromethane (100 mL) was added into a suspension of aminoester (0.05 mol) in the same solvent (120 mL) at 0 °C. The reaction was complete in 45 minutes. The reaction mixture was then diluted with dichloromethane (100 mL) and washed with two portions of 0.1 N HCl solution. The organic layer was dried with (Na$_2$SO$_4$) and concentrated in vacuo to give the crude product, which was purified by column chromatography eluting with dichloromethane to give compounds 1 and 2.

(S)-Methyl [N-methyl(N’-tert-butyloxycarbonyl)-sulfamoyl]-glycinate (1). Yield = 80%; TLC: Rf = 0.76 (CH$_2$Cl$_2$-MeOH 9:1); crystallizable oil; IR (KBr) $\nu$ cm$^{-1}$: 3200 (NH), 1770, 1763 (C=O), 1360 and 1150 (SO$_2$); $^1$H-NMR (CDCl$_3$) $\delta$ ppm: 7.62 (s, 1H, NH), 4.14 (s, 2H, CH$_2$), 3.75 (s, 3H, OCH$_3$), 3.04 (s, 3H, NCH$_3$), 1.49 (s, 9H, tBu); M.S: (NOBA, FAB > 0): 283 [M+H]$^+$, 565. M = 282; Anal. Calcd for C$_9$H$_{18}$N$_2$O$_6$S: C, 38.29; H, 6.38; N, 9.93; S, 11.34; found: C, 38.24; H, 6.43; N, 9.87; S, 11.28.

(S)-Methyl [N-(N’-tert-butyloxycarbonyl)-sulfamoyl]-prolinate (2). Yield = 80%; TLC: Rf = 0.58 (CH$_2$Cl$_2$-MeOH 95:5); m.p. = 132–133 °C; $[\alpha]_D$ = -9.5 (c = 1; MeOH); IR (KBr) $\nu$ cm$^{-1}$: 1730, 1712 (C=O), 1340 and 1150 (SO$_2$); $^1$H-NMR (CDCl$_3$) $\delta$ ppm: 7.52 (s, 1H, NH); M.S: (NOBA, FAB > 0): 309 [M+H]$^+$, 208 ([M+H]$^+$-Boc). M = 308; Anal. Calcd for C$_{11}$H$_{20}$N$_2$O$_6$S: C, 42.85; H, 6.69; N, 9.09; S, 10.38; found: C, 42.27; H, 6.53; N, 9.06; S, 10.41.
3.3. General Procedure for the Synthesis of \( N\)-Boc, \( N'\)-(benzyl)sulfamides 1a and 2a

A solution of \( N\)-alkyl carboxylsulfamide (0.0065 mol, 2 g), triphenylphosphine (2.56 g) and benzylic alcohol (0.7 g) in THF (15 mL) was added dropwise (20 min, 5 °C) to a solution of equimolar quantities of diethyl(diisopropyl)azodicarboxylate (1.97 g) in THF (5 mL), the reaction medium was stirred under an atmosphere of dry nitrogen for about 45 min. TLC reveals the formation of substituted compound (UV, ninhydrin) less polar than its precursor. Oxidoreduction compounds were removed by filtration after precipitation into diethylether. The filtrate was concentrated and the crude residue was purified by column chromatography eluted with dichloromethane.

\((S)\)-Methyl \( [N-(N'\text{-tert-butyloxycarbonyl, } N'\text{-benzyl})\text{-sulfamoyl}]\)-glycinate (1a). Yield = 80%; TLC: \( R_f = 0.76 \) (CH\( _2Cl_2\)-MeOH 95:5); m.p. = 72 °C; \(^1H\)-NMR (CD\( Cl_3\)) \( \delta \) ppm: 7.34 (m, 5H, ArH), 4.86 (s, 2H, CH\( _2\)-ph), 4.04 (s, 2H, CH\( _2\)-N), 3.72 (s, 3H, OCH\( _3\)), 2.84 (s, 3H, CH\( _3\)), 1.49 (s, 9H, tBu); M.S: (NOBA, FAB > 0): 373 [M+H]\(^+\). M = 372; Anal. Calcd for C\( _{16}H_{24}N_2O_6S\): C, 51.61; H, 6.45; N, 7.52; S, 8.60; found: C, 51.43; H, 6.38; N, 7.49; S, 8.62.

\((S)\)-Methyl \( [N-(N'\text{-tert-butyloxycarbonyl, } N'\text{-benzyl})\text{-sulfamoyl}]\)-prolinate (2a). Yield = 85%; TLC: \( R_f = 0.73 \) (CH\( _2Cl_2\)-MeOH 95:5); m.p. = 73 °C; \(^1H\)-NMR (CD\( Cl_3\)) \( \delta \) ppm: 7.36 (m, 5H, ArH), 4.86 (m, 1H, CH), 4.66 (2dd, 2H, \( J = 3.14, 5.45 \) Hz, CH\( _2\)-Ph), 3.72 (s, 3H, OCH\( _3\)), 3.48 (m, 1H, CH\( ^*\)), 3.15 (m, 1H, CH), 1.88–2.08 (m, 4H, 2CH\( _2\)), 1.48 (s, 9H, tBu); M.S: (NOBA, FAB > 0): 399 [M+H]\(^+\). M = 398; Anal. Calcd for C\( _{18}H_{26}N_2O_6S\): C, 54.71; H, 6.53; N, 7.03; S, 8.04; found: C, 54.65; H, 6.62; N, 7.05; S, 8.13.

3.4. General Deprotection Procedure: Preparation of 1b and 2b

A solution of trifluoroacetic acid (50% in dichloromethane; 3 equiv.) was dropwise added into a stirred solution of substituted \( N\)-carboxylsulfamide (0.92 g, 2.6 mmol) in dichloromethane (10 mL) at 0 °C. The reaction medium was stirred during two hours, concentrated under reduced pressure and coevaporated with diethylether. The residue was purified by column chromatography eluted with dichloromethane (or recrystallized from an AcOEt-hexane mixture) to afford deprotected sulfamides 1b and 2b.

\( N[N'\text{-Benzyl}\text{-sulfamoyl}][\text{glycinate de methyl} (1b). Yield = 95%; TLC: \( R_f = 0.55 \) (CH\( _2Cl_2\)-MeOH 95:5); m.p. = 100–102 °C; IR (KBr) \( \nu \) cm\(^{-1}\): 3312 (NH), 1360 and 1160 (SO\( _2\)); \(^1H\)-NMR (CD\( Cl_3\)) \( \delta \) ppm: 7.34 (m, 5H, ArH), 5.70 (t, 1H, NH), 4.30 (d, 2H, \( J = 6.0 \) Hz, CH\( _2\)-Ph), 4.0 (s, 2H, CH\( _2\)), 3.75 (s, 3H, OCH\( _3\)), 2.90 (s, 3H, CH\( _3\)); M.S: (NOBA, FAB > 0): 273 [M+H]\(^+\), 546; M = 272; Anal. Calcd for C\( _{11}H_{16}N_2O_4S\): C, 48.52; H, 5.88; N, 10.29; S, 11.76; found: C, 48.39; H, 5.80; N, 10.25; S, 11.74.

\( N[N'\text{-Benzyl}\text{-sulfamoyl}][\text{prolinate de methyl} (2b). Yield = 98%; TLC: \( R_f = 0.60 \) (CH\( _2Cl_2\)-MeOH 95:5); oil; IR (KBr) \( \nu \) cm\(^{-1}\): 3320 (NH), 1355 and 1159 (SO\( _2\)); \(^1H\)-NMR (CD\( Cl_3\)) \( \delta \) ppm: 7.34 (m, 5H, ArH), 5.96 (m, 1H, NH), 4.41 (dd, 1H, \( J = 3.81, 4.70 \) Hz, C\( ^*\)H), 4.30 (2dd, 2H, \( J = 3.11, 4.70 \) Hz, CH\( _2\)-Ph), 3.70 (s, 3H, OCH\( _3\)), 3.46 (m, 2H, CH\( _2\)), 2.20–2.0 (m, 4H, CH\( _2\beta\) and CH\( _2\gamma\)); M.S: (NOBA, FAB > 0): 299 [M+H]\(^+\). M = 298; Anal. Calcd for C\( _{13}H_{18}N_2O_4S\): C, 52.34; H, 6.04; N, 9.39; S, 10.73; found: C, 52.29; H, 6.00; N, 9.37; S, 10.68.
3.5. General Reduction Procedure; Preparation of 1c and 2c

Deprotected product 1b or 2b (3.30 mmol) in THF (15 mL) was added dropwise to a suspension of NaBH₄ (0.006 mol) in THF-Water (4:1, v/v, 20 mL) at 0 °C. When the addition was complete, the reaction mixture was acidified slowly with HCl 5% and concentrated in vacuo. The aqueous layer was extracted with ethyl acetate (3 × 150 mL). The combined organic layers were dried (Na₂SO₄) and concentrated in vacuo. The crude product was purified by column chromatography eluted with dichlomethane-methanol (90:10).

N-Methyl(N'-(benzylsulfamoyl) glycino)(1c). Yield = 87%; TLC: Rf = 0.50 (CH₂Cl₂-MeOH 95:5); m.p. = 98 °C; IR (KBr) v cm⁻¹: 3315 (NH), 1330 (OH); ¹H-NMR (CDCl₃) δ ppm: 7.35 (m, 5H, ArH), 4.72 (t, 1H, NH), 4.39 (d, 2H, J = 5.99 Hz, CH₂-Ph), 3.78 (t, 2H, CH₂OH), 3.35 (t, 2H, CH₂N), 2.88 (s, 3H, CH₃), 1.98 (s, 1H, OH); M.S: (ESI⁺): 267 [M+Na]⁺, 511 [2M+Na]⁺; M = 244; Anal. Calcd for C₁₀H₁₆N₂O₃S: C, 49.18; H, 6.55; N, 11.47; S, 13.11; found: C, 49.14; H, 6.52; N, 11.45; S, 13.20.

3.6. General Procedure for the Preparation of 1,4,3,5-Oxathiadiazepanes 4,4-dioxides 1d–4d, 1e–4e

Compounds 1c and 2c (0.01 mol) were dissolved separately in dichloromethane (25 mL), and the aromatic aldehyde (0.01 mol) was added. A drop of concentrated sulfuric acid was also added, and the reaction mixture was stirred for 3h at room temperature. The reaction mixture was washed with a 5% solution of sodium bicarbonate, water and then with brine. The organic layer was dried over anhydrous sodium sulfate, and evaporated under reduced pressure on a rotary evaporator. The residue was purified by column chromatography eluting with dichloromethane to give the 1,4,3,5-oxathiadiazepanes 4,4-dioxide.

(N³,2)-Dibenzyl, N⁵-methyl 1,4,3,5-oxathidiazepane 4,4-dioxyde (1d). Yield = 59%; TLC: Rf = 0.75 (CH₂Cl₂); m.p. = 82–85 °C; IR (KBr): ¹H-NMR (CDCl₃) δ ppm: 7.30 (m, 10H, 2ArH), 7.09 (m, 2H, C*-CH₂-ph), 5.1 (t, J = 5.37, 1H, CH*), 4.55 (s, 2H, CH₂-N), 3.90 (m, 2H, CH₂-O), 2.97 (S, 3H, CH₃-N), 2.85 (m, 2H, CH₂-N); ¹³C-NMR (CDCl₃) δ ppm: 37.80, 41.34, 49.74, 52.80, 68, 89.31, 128; M.S: (ESI⁺): 369 [M+Na]⁺, 563 [2M+Na]⁺; M = 346; Anal. Calcd for C₁₈H₁₈N₂O₃S: C, 62.42; H, 6.06; N, 8.09; S, 9.24; found: C, 62.44; H, 6.02; N, 8.03; S, 9.20.

(N³,Benzyl, N⁵-methyl, 2-phenyl 1,4,3,5-oxathidiazepane 4,4-dioxyde (2d). Yield = 50%; TLC: Rf = 0.75 (CH₂Cl₂); oil: ¹H-NMR (CDCl₃) δ ppm: 7.80 (dd, J = 1.37, 1.55 Hz, 1H, CH*), 7.30 (m, 10H, 2Ar), 4.35 (t, 2H, CH₂-O), 4.25 (dd, J = 27.57, 27.52 Hz, 2H, CH₂-Ph), 3.30 (t, 2H, CH₂-N), 2.90 (S, 3H, CH₃-N); ¹³C-NMR (CDCl₃) δ ppm: 37.80, 49.70, 52.80, 68, 87.50, 128.50; (ESI⁺): 355 [M+Na]⁺;
M = 332; Anal. Calcd for C_{17}H_{20}N_{2}O_{3}S: C, 61.44; H, 6.02; N, 8.43; found: C, 61.40; H, 6.10; N, 8.50; S, 9.67.

N²-Benzyl, N⁵-methyl, 2-(2-chlorophenyl) 1,4,3,5-oxathiazepane 4,4-dioxide (3d). Yield = 43%; TLC: Rf = 0.80 (CH₂Cl₂); m.p. = 80–82 °C; ¹H-NMR (CDCl₃) δ ppm: 7.90 (d, J = 1.47 Hz, 1H, CH*), 7.40 (m, 9H, 2Ar), 4.50 (t, J = 5.49 Hz, 2H, CH₂-O), 4.20 (d, J = 5.98 Hz, 2H, CH₂-Ph), 3.57 (t, J = 5.49 Hz, 2H, CH₂-N), 2.92 (s, 3H, CH₃-N); ¹³C-NMR (CDCl₃) δ ppm: 37.80, 49.50, 53.0, 68.4, 84.60, 129, 132; M.S: (ESI+): 389 [M+Na]⁺; M = 366; Anal. Calcd for C_{17}H_{19}N_{2}O_{3}SCl: C, 55.73; H, 5.19; N, 7.65; S, 8.70.

N²-Benzyl, N⁵-methyl, 2-(4-chlorophenyl) 1,4,3,5-oxathiazepane 4,4-dioxide (4d). Yield = 41%; TLC: Rf = 0.80 (CH₂Cl₂); m.p. = 80–82 °C; ¹H-NMR (CDCl₃) δ ppm: 7.50 (d, J = 1.49 Hz, 1H, CH*), 7.20 (m, 9H, 2Ar), 4.30 (t, J = 1.63 Hz, 2H, CH₂-O), 4.1 and 4.4 (2d, J = 15.89 Hz, 1H and J = 15.91 Hz, 1H, CH₂-Ph), 3.5 (t, J = 1.49, 2H, CH₂-N), 3.10 (s, 3H, CH₃-N); ¹³C-NMR (CDCl₃) δ ppm: 37.80, 49.50, 55.90, 68.3, 85.0, 129, 131.5; M.S: (ESI+): 389 [M+Na]⁺; M = 366; Anal. Calcd for C_{17}H_{19}N_{2}O_{3}SCl: C, 55.73; H, 5.23; N, 7.72; S, 8.70.

(N³,2)-Dibenzyl, (N⁵,6)-trimethylene 1,4,3,5-oxathiadiazepane 4,4-dioxide (1e). Yield = 55%; TLC: Rf = 0.82 (CH₂Cl₂); m.p. = 107–108 °C; ¹H-NMR (CDCl₃) δ ppm: 7.30 (m, 10H, 2ArH), 5.48 (dd, J = 3.43, J = 3.49 Hz, 1H, C₁H*), 5.31 (s, 2H, CH₂-N), 4.81 and 4.55 (2d, J = 16.77 Hz, 1H and J = 16.68 Hz, 1H, CH₂-Ph), 3.81 (m, 2H, CH₂-O), 3.50 (m, 2H, CH₂-N and C₂H*-N), 1.35 (m, 4H, CH₂β and CH₂γ); ¹³C-NMR (CDCl₃) δ ppm: 24.80, 28.97, 41.41, 48.19, 59.15, 73.06, 89.98, 129; M.S: (ESI+): 395 [M+Na]⁺; M = 372; Anal. Calcd for C_{20}H_{24}N_{2}O_{3}S: C, 64.5; H, 6.45; N, 7.52; S, 8.60; found: C, 64.49; H, 6.46; N, 7.47; S, 8.65.

2-Phenyl, N³-benzyl, (N⁵,6)-trimethylene 1,4,3,5-oxathiadiazepane 4,4-dioxide (2e). Yield = 45%; TLC: Rf = 0.79 (CH₂Cl₂); m.p. = 97–99 °C; ¹H-NMR (CDCl₃) δ ppm: 7.90 (dd, J = 1.53, J = 1.57 Hz, 1H, C₁H*), 7.45 (m, 10H, 2ArH), 4.30 (s, 2H, CH₂-Ph), 3.90 (m, 1H, C₂H*), 3.70–3.60 (m, 2H, CH₂-O), 3.50 (m, 2H, CH₂-N), 1.80 (m, 4H, CH₂β and CH₂γ); ¹³C-NMR (CDCl₃) δ ppm: 24.80, 28.97, 41.48, 59.15, 72.80, 89.80, 129; M.S: (ESI+): 381 [M+Na]⁺; M = 358; Anal. Calcd for C_{19}H_{22}N_{2}O_{3}S: C, 63.68; H, 6.14; N, 7.82; S, 8.93; found: C, 63.72; H, 6.16; N, 7.79; S, 8.89.

2-(2-Chlorophenyl), N³-benzyl, (N⁵,6)-trimethylene 1,4,3,5-oxathiadiazepane 4,4-dioxide (3e). Yield = 40%; TLC: Rf = 0.80 (CH₂Cl₂); oil; ¹H-NMR (CDCl₃) δ ppm: 6.94 (m, 9H, 2ArH), 6.52 (s, 1H, C₁H*), 4.50 (dd, J = 15.81, J = 16.24 Hz, 2H, CH₂-Ph), 4.10–3.90 (m, 3H, CH₂-O and C₂H*), 3.60 (t, 2H, CH₂-N), 2.08 (m, 2H, CH₂β), 1.60 (m, 2H, CH₂γ); ¹³C-NMR (CDCl₃) δ ppm: 24.80, 28.97, 41.48, 59.15, 72.80, 89.80, 129, 131.5; M.S: (ESI+): 415 [M+Na]⁺; M = 392.5; Anal. Calcd for C_{19}H_{21}N_{2}O_{3}SCl: C, 58.08; H, 5.35; N, 7.13; S, 8.15; found: C, 58.00; H, 5.29; N, 7.09; S, 8.20.

2-(4-Chlorophenyl), N³-benzyl, (N⁵,6)-trimethylene 1,4,3,5-oxathiadiazepane 4,4-dioxide (4e). Yield = 42%; TLC: Rf = 0.78 (CH₂Cl₂); yellow powder, m.p. = 154–157 °C; ¹H-NMR (CDCl₃) δ ppm: 7.25 (m, 9H, 2ArH), 6.35 (s, 1H, C₁H*), 4.48 (dd, J = 15.85, J = 16.21 Hz, 2H, CH₂-Ph), 4.11 (m, 1H, C₂H*), 3.85 (m, 2H, CH₂-O), 3.55 (m, 2H, CH₂-N), 2.15 (m, 4H, CH₂β and CH₂γ); ¹³C-NMR (CDCl₃)
δ ppm: 24.80, 28.97, 41, 48.20, 59.15, 72.80, 89.80, 129, 131; M.S: (ESI+): 415 [M+Na]⁺, 807 [2M+Na]⁺; M = 392.5; Anal. Calcd for C₁₀H₂₁N₂O₃SCl: C, 58.08; H, 5.35; N, 7.13; S, 8.15; found: C, 58.10; H, 5.39; N, 7.16; S, 8.19.

4. Conclusions

In conclusion, we have successfully prepared a new class of seven-membered heterocyclic substituted 1,4,3,5-oxathiadiazepanes 4,4-dioxides via a simple strategy. The biological evaluation of the resulting compounds, their stereochemical study, reopening after debenzylation by nucleophilic attack by organometallic reagents and their incorporation into biomolecule analogues are currently underway and will be reported in due course.

Acknowledgments

This work was partially supported by Algerian Research Ministry, MERS.

References and Notes

1. Drews, J. Drug Discovery: A Historical Perspective. Science 2000, 287, 1960–1964.
2. Scozzafava, A.; Owa, T.; Mastrolorenzo, A.; Supuran, C.T. Update on the Development of HIV Entry Inhibitors. Curr. Med. Chem. 2003, 10, 925–953.
3. Silvestri, R.; Marfe, G.; Artico, M.; la Regina, G.; Lavecchia, A.; Novellino, E.; Morgante, M.; di Stefano, C.; Catalano, G.; Filomeni, G.; Abruzzese, E.; Cirillo, M.R.; Russo, M.A.; Amadori, S.; Cirilli, R.; la Torre, F.; Salimei, P.S. Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): A New Class of Agents with High Apoptotic Activity in Chronic Myelogenous Leukemia K562 Cells and in Cells from Patients at Onset and Who Were Imatinib-Resistant. J. Med. Chem. 2006, 49, 5840–5844.
4. Lebegue, N.; Gallet, S.; Flouquet, N.; Carato, P.; Pfeiffer, B.; Renard, P.; Le’once, S.; Pierre, A.; Chavatte, P.; Berthelot, P. Novel Benzopyridothiadiazepines as Potential Active Antitumor Agents. J. Med. Chem. 2005, 48, 7363–7373.
5. Brzozowski, F.; Saczewski, F.; Neamati, N. Synthesis and anti-HIV-1 activity of a novel series of 1,4,2-benzodithiazine-dioxides. Bioorg. Med. Chem. Lett. 2006, 16, 5298–5302.
6. Iyenger, B.S.; Dorr, R.T.; Alberts, D.S.; Solyom, A.M.; Krutzsch, M.; Remers, W.A. 1,4-Disubstituted Anthracene Antitumor Agents. J. Med. Chem. 1997, 40, 3734–3738.
7. Thurston, D.E.; Subhas, B.D.; Howard, P.W.; Jen-kins, T.C.; Leoni, A.; Baraldi, P.G.; Guiotto, A.; Cacciari, B.; Kelland, L.R.; Follope, M.; Rault, S.J. Effect of A-Ring Modifications on the DNA-Binding Behavior and Cytotoxicity of Pyrrolo[2,1-c][1,4]benzodiazepines. J. Med. Chem. 1999, 42, 1951–1964.
8. Basolo, L.; Beccalli, E.M.; Borsini, E.; Broggi, G.; Khansaa, M.; Rigamonti, M. Access to a Novel Class of Tetracyclic 1,4-Benzodiazepin-5-ones Starting from α-Amino Acids by Pd-Catalyzed Amination/1,3-Dipolar Cycloaddition as the Key Steps. Eur. J. Org. Chem. 2010, 2010, 1694–1703.
9. Mowbray, C.E.; Burt, C.; Corbau, R.; Gayton, S.; Hawes, M.; Perros, I.; Tran, D.A.; Price, F.J.; Quinton, M.D.; Selby, P.A.; Stuckle, R.; Webster, A.W. Pyrazole NNRTIs 4: Selection of UK-453,061 (lersivirine) as a Development Candidate. *Bioorg. Med. Chem. Lett.* 2009, 19, 5857–5860.

10. Broggini, G.; Marchi, I.; Martinelli, M.; Paladino, G.; Pilati, T.; Terraneo, A. Effective Synthesis of Enantiopure [1,2,3]Triazolo[1,5-a] and Pyrazolo[1,5a]pyrrolo[2,1c][1,4] benzodiazepines by Diastereoselective Intramolecular Azide and Nitrilimine Cycloadditions. *Synthesis* 2005, 2246–2252.

11. Hurley, L.H.; Petrusek, R.L. Proposed structure of the anthramycin-DNA adduct. *Nature* 1979, 282, 529–531.

12. Cheatham, S.; Kook, A.; Hurley, L.H.; Barkley, M.D.; Remers, W.J. One and two dimensional proton NMR, fluorescence and molecular modeling studies on the tomaymycin-d(ATGCAT)2 adduct. Evidence for two covalent adducts with opposite orientations and stereochemistries at the covalent linkage site. *J. Med. Chem.* 1988, 31, 583–590.

13. Wang, J.J.; Hill, G.C.; Hurley, L.H. Template-directed design of a DNA-DNA crosslinker based upon a bis-tomaymycin-duplex adduct. *J. Med. Chem.* 1992, 35, 2995–3002.

14. Montzouris, J.A.; Wang, J.J.; Thurston, D.E.; Hurley, L.H. Comparison of a DSB-120 DNA Interstrand Cross-Linked Adduct with the Corresponding Bis-tomaymycin Adduct: An Example of a Successful Template-Directed Approach to Drug Design Based upon the Monoalkylating Compound Tomaymycin. *J. Med. Chem.* 1994, 37, 3132–3140.

15. Boudjabi, S.; Dewynter, G.; Voyer, N.; Toupet, L.; Montero, J.L. Sulfahydantoins as Tripeptide Constraints: Synthesis and Structure of Chiral Substituted 3-Oxo-1,2,5-thiadiazolidine 1,1-Dioxides. *Eur. J. Org. Chem.* 1999, 2275–2283.

16. Regainia, Z.; Abdaoui, M.; Aouf, N.E.; Dewynter, G.; Montero, J.L. Synthesis of 1,2,5-Thiadiazolidines 1,1-dioxides (Cyclosulfamides) Starting from Amino Acids and Chlorosulfonyl Isocyanate. *Tetrahedron* 2000, 56, 381–387.

17. Berredjem, M.; Djebbar, H.; Regainia, Z.; Aouf, N.E.; Dewynter, G.; Winum, J.Y.; Montero, J.L. Synthese et N-Acylation Regiospecifique de 1,2,5-Thiadiazolidines 1,1-Dioxydes Chiraux. *Phosphorus Sulfur* 2003, 178, 693–705.

18. Regainia, Z.; Winum, J.Y.; Smain, F.Z.; Toupet, L.; Aouf, N.E.; Montero, J.L. General synthesis of n-membered cyclic sulfamides. *Tetrahedron* 2003, 59, 6051–6056.

19. Bendjeddou, A.; Djeribi, R.; Regainia, Z.; Aouf, N. N,N'-Substituted 1,2,5 Thiadiazolidine 1,1-Dioxides: Synthesis, Selected Chemical and Spectral Properties and Antimicrobial Evaluation. *Molecules* 2005, 10, 1387–1398.

20. Kumar, G.B.; Patel, H.V.; Shah, A.C.; Trenkle, M.; Cardin, C.J. Diastereoselective formation of 2-aryl-3-arenesulfonyl 4-ethyl-1,3-oxazolidines: An X-ray crystallographic and 1H NMR study. *Tetrahedron-Asymmetry* 1996, 7, 3391–3396.

21. Wilken, J.; Wallbaum, S.; Saak, W.; Haase, D.; Pohl, S.; Laxmikant, N.; Patkar, N.; Arun, N.; Chittari, P.; Rajappa, S.; Martens, J. Utilization of Industrial Waste Materials, 6. Utilization of Derivatives of the Bicyclic Proline Analog (all-R-Octahydrocyclopenta[b]pyrrol-2-carboxylic Acid in the Stereoselective Synthesis. *Liebig's Ann.* 1996, 927–934.
22. Heydenreich, M.; Koch, A.; Lazar, L.; Szatmari, I.; Sillanpaa, R.; Kleinpeter, E.; Fulop, F. Synthesis and stereochemical studies of 1- and 2-phenyl-substituted 1,3-oxazino[4,3-\(a\)]isoquinoline derivatives. *Tetrahedron* **2003**, *59*, 1951–1959.

23. Perlmutter, P.; Tabone, M. A Simple Route to \(\alpha\)-Substituted-\(\beta\)-Amino Ester Precursors of Carbapenem Antibiotics. *J. Org. Chem.* **1995**, *60*, 6515–6522.

24. Arnecke, R.; Bohmer, V.; Friebe, S.; Gebauer, S.; Krauss, G.J.; Thondorf, I.; Vgt, W. Regio- and diastereoselective condensation of resorcanes with primary amines and formaldehyde. *Tetrahedron Lett.* **1995**, *36*, 6221–6224.

25. Mitsunobu, O. The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products. *Synthesis* **1981**, *1*, 1–29.

26. Hughes, D.L. The Mitsunobu Reaction. *Org. Reactions* **1992**, *42*, 335–380.

27. Takahashi, H.; Morimoto, I.; Higashiyama, K. Highly Diastereoselective Reaction of (3aS,6R)-5-Oxa-7,8a-diazaperhydroazulen-8-ones with Diethylzinc. *Chem. Pharm. Bull.* **1990**, *38*, 2627–2631.

28. Takahashi, H.; Morimoto, I.; Higashiyama, K. Asymmetry Induction by Chiral Heterocyclic Compounds: Highly Diastereoselective Reaction of 5-Oxa-7,8a-diazaperhydroazulen-8-ones with Organometallic Reagents. *Heterocycles* **1990**, *30*, 287–290.

*Sample Availability*: Samples of the compounds 1d–4d and 1e–4e are available from the authors.

© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).